Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

106
Delayed Quote. Delayed Nyse - 04/23 11:49:00 am
57.415 USD   -0.61%
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
2d ago AstraZeneca cancer pipeline seen as draw for Pfizer
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern
Recommend:
0

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
2d ago AstraZeneca cancer pipeline seen as draw for Pfizer
6d ago MERCK : FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allerge..
6d ago MERCK : FDA OKs Merck tablet to reduce ragweed allergies
6d agoDJEuropean Regulator Warns of More Drug Tampering
6d ago MERCK : Study Findings from Merck & Company Provide New Insights into Connective..
7d ago MERCK : Findings from Merck & Company in the Area of Adenosine Therapy Described
04/16 Reckitt leans towards pharmaceuticals spin-off
04/15 Cargill expects flour merger with ConAgra to be finalized in 6-8 weeks
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF